Valuation: Astellas Pharma Inc.

Capitalization 2,481B 16.93B 14.46B 13.48B 12.47B 23.2B 1,452B 25.94B 161B 61.39B 678B 63.51B 62.2B P/E ratio 2026 *
18.4x
P/E ratio 2027 * 12x
Enterprise value 2,942B 20.08B 17.15B 15.98B 14.78B 27.51B 1,721B 30.76B 191B 72.79B 804B 75.31B 73.75B EV / Sales 2026 *
1.51x
EV / Sales 2027 * 1.33x
Free-Float
98.67%
Yield 2026 *
5.71%
Yield 2027 * 5.97%
More valuation ratios * Estimated data
Dynamic Chart
1 day-0.65%
1 week-1.04%
Current month-2.79%
1 month-2.86%
3 months+3.26%
6 months-8.81%
Current year-10.26%
More quotes
1 week 1,365
Extreme 1365
1,407.5
1 month 1,343.5
Extreme 1343.5
1,432
Current year 1,243.5
Extreme 1243.5
1,559.5
1 year 1,243.5
Extreme 1243.5
1,835
3 years 1,243.5
Extreme 1243.5
2,360.5
5 years 1,243.5
Extreme 1243.5
2,360.5
10 years 1,243.5
Extreme 1243.5
2,360.5
More quotes
Manager TitleAgeSince
Chief Executive Officer 62 2023-02-09
Director of Finance/CFO 53 2023-10-31
Compliance Officer - 2025-03-31
Director TitleAgeSince
Chairman 65 2023-02-09
Director/Board Member 62 2019-05-31
Director/Board Member 68 2021-05-31
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-0.65%-1.04%-15.52%-36.37% 16.93B
+1.19%+0.98%-15.61%+138.12% 706B
+0.31%+0.46%+6.28%-12.34% 376B
+0.45%-0.07%+13.43%+24.71% 337B
+0.08%+1.44%-54.50%+9.54% 309B
+0.37%+1.28%+4.78%-20.08% 262B
+1.16%+1.96%+0.41%+18.92% 240B
+2.26%+3.86%-12.26%-4.99% 218B
+2.88%+1.60%-33.58%-9.78% 210B
-0.16%-0.11%-6.14%+19.33% 159B
Average +0.33%+0.43%-11.27%+12.71% 283.46B
Weighted average by Cap. +0.32%+0.43%-10.79%+36.27%
See all sector performances

Financials

2026 *2027 *
Net sales 1,943B 13.26B 11.32B 10.55B 9.76B 18.16B 1,136B 20.31B 126B 48.06B 531B 49.72B 48.69B 2,039B 13.92B 11.89B 11.08B 10.25B 19.07B 1,193B 21.32B 133B 50.45B 557B 52.2B 51.12B
Net income 134B 913M 780M 727M 672M 1.25B 78.29B 1.4B 8.7B 3.31B 36.58B 3.43B 3.35B 208B 1.42B 1.21B 1.13B 1.04B 1.94B 121B 2.17B 13.49B 5.13B 56.72B 5.31B 5.2B
Net Debt 461B 3.15B 2.69B 2.5B 2.32B 4.31B 270B 4.82B 29.97B 11.4B 126B 11.8B 11.55B 234B 1.6B 1.36B 1.27B 1.17B 2.19B 137B 2.44B 15.2B 5.78B 63.91B 5.99B 5.86B
More financial data * Estimated data
Logo Astellas Pharma Inc.
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.
Employees
13,643
Calendar
More about the company
Date Price Change Volume
25-07-10 1,377.00 ¥ -0.65% 6,917,400
25-07-09 1,386.00 ¥ +1.54% 6,574,100
25-07-08 1,365.00 ¥ -1.23% 7,751,000
25-07-07 1,382.00 ¥ -1.43% 4,730,900
25-07-04 1,402.00 ¥ +0.75% 4,580,400

Delayed Quote Japan Exchange, July 10, 2025 at 02:30 am EDT

More quotes
Trading Rating
Investor Rating
ESG MSCI
AAA
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
1,386.00JPY
Average target price
1,689.29JPY
Spread / Average Target
+21.88%
Consensus

Quarterly revenue - Rate of surprise